1-4 of 4
Jeffrey A. Ecsedy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models

Yan Liu, Oriana E. Hawkins, Anna E. Vilgelm, Jeffrey S. Pawlikowski, Jeffrey A. Ecsedy, Jeffrey A. Sosman, Mark C. Kelley, Ann Richmond
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (23): 5338–5348.
https://doi.org/10.1158/1078-0432.CCR-15-0293
Published: 30 November 2015
View article titled, Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models
Open the PDF for Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models in another window
Includes: Supplementary data
Journal Articles

The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo

Ning Zhou, Kamini Singh, Maria C. Mir, Yvonne Parker, Daniel Lindner, Robert Dreicer, Jeffrey A. Ecsedy, Zhongfa Zhang, Bin T. Teh, Alexandru Almasan, Donna E. Hansel
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1717–1728.
https://doi.org/10.1158/1078-0432.CCR-12-2383
Published: 02 April 2013
View article titled, The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells <em>In Vitro</em> and <em>In Vivo</em>
Open the PDF for The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells <em>In Vitro</em> and <em>In Vivo</em> in another window
Includes: Supplementary data
Journal Articles

Ras-Driven Transcriptome Analysis Identifies Aurora Kinase A as a Potential Malignant Peripheral Nerve Sheath Tumor Therapeutic Target

Ami V. Patel, David Eaves, Walter J. Jessen, Tilat A. Rizvi, Jeffrey A. Ecsedy, Mark G. Qian, Bruce J. Aronow, John P. Perentesis, Eduard Serra, Timothy P. Cripe, Shyra J. Miller, Nancy Ratner
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (18): 5020–5030.
https://doi.org/10.1158/1078-0432.CCR-12-1072
Published: 16 September 2012
View article titled, Ras-Driven Transcriptome Analysis Identifies Aurora Kinase A as a Potential Malignant Peripheral Nerve Sheath Tumor Therapeutic Target
Open the PDF for Ras-Driven Transcriptome Analysis Identifies Aurora Kinase A as a Potential Malignant Peripheral Nerve Sheath Tumor Therapeutic Target in another window
Includes: Supplementary data
Journal Articles

Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays

Mark G. Manfredi, Jeffrey A. Ecsedy, Arijit Chakravarty, Lee Silverman, Mengkun Zhang, Kara M. Hoar, Stephen G. Stroud, Wei Chen, Vaishali Shinde, Jessica J. Huck, Deborah R. Wysong, David A. Janowick, Marc L. Hyer, Patrick J. LeRoy, Rachel E. Gershman, Matthew D. Silva, Melissa S. Germanos, Joseph B. Bolen, Christopher F. Claiborne, Todd B. Sells
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (24): 7614–7624.
https://doi.org/10.1158/1078-0432.CCR-11-1536
Published: 18 December 2011
View article titled, Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel <em>In Vivo</em> Pharmacodynamic Assays
Open the PDF for Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel <em>In Vivo</em> Pharmacodynamic Assays in another window
Includes: Supplementary data